FZD6: A Potential Drug Target for T-cell Regulation and Immune Cell Function

Target Name: FZD6

NCBI ID: G8323

FZD6

FZD6: A Potential Drug Target for T-cell Regulation and Immune Cell Function

FZD6, also known as FZD6 variant 1, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the T-cell receptor (TCR) family and is involved in the regulation of cell growth, differentiation, and survival.

FZD6 has been identified as a potential drug target and is currently being studied in various clinical trials. Its potential as a drug target is based on its involvement in the regulation of immune cells, including T-cells.

One of the key functions of T-cells is their ability to recognize and respond to foreign substances in the body, such as viruses and bacteria. T-cells are a crucial part of the immune system and play a major role in fighting off infections and diseases.

FZD6 is involved in the regulation of T-cell development and function. It has been shown to play a role in the development and regulation of CD4+ T-cells, which are a crucial part of the immune system.

In addition to its role in T-cell development, FZD6 has also been shown to be involved in the regulation of T-cell death. Studies have shown that FZD6 can induce cell death in T-cells under certain conditions, which may be a potential mechanism for its anti-inflammatory effects.

FZD6 has also been shown to be involved in the regulation of inflammation. Studies have shown that FZD6 can inhibit the production of pro-inflammatory cytokines, which play a key role in the regulation of inflammation.

In addition to its potential role in T-cell regulation, FZD6 has also been shown to have potential as a drug target in other contexts. For example, it has been shown to play a role in the regulation of cell adhesion, which is the process by which cells stick together and form tissues.

FZD6 has also been shown to be involved in the regulation of cell signaling pathways, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell growth, differentiation, and survival, and is a key target for many diseases.

In conclusion, FZD6 is a protein that is involved in a number of important biological processes in the body. Its potential as a drug target makes it an attractive target for research into the regulation of immune cells and other processes. Further studies are needed to fully understand its role in these processes and its potential as a drug.

Protein Name: Frizzled Class Receptor 6

Functions: Receptor for Wnt proteins. Most of frizzled receptors are coupled to the beta-catenin canonical signaling pathway, which leads to the activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin and activation of Wnt target genes. A second signaling pathway involving PKC and calcium fluxes has been seen for some family members, but it is not yet clear if it represents a distinct pathway or if it can be integrated in the canonical pathway, as PKC seems to be required for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to involve interactions with G-proteins. May be involved in transduction and intercellular transmission of polarity information during tissue morphogenesis and/or in differentiated tissues. Together with FZD3, is involved in the neural tube closure and plays a role in the regulation of the establishment of planar cell polarity (PCP), particularly in the orientation of asymmetric bundles of stereocilia on the apical faces of a subset of auditory and vestibular sensory cells located in the inner ear (By similarity)

The "FZD6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FZD6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets